Skip to main content
. Author manuscript; available in PMC: 2021 Jul 25.
Published in final edited form as: Nat Genet. 2021 Jan 25;53(2):128–134. doi: 10.1038/s41588-020-00762-2

Figure 5. A polygenic risk score for HCM stratifies event-free survival in carriers of disease-causing variants in sarcomere-encoding genes.

Figure 5

Kaplan-Meier curves showing survival free from adverse clinical events (composite of septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate implantable cardioverter defibrillator [ICD] therapy or atrial fibrillation/flutter) in sarcomeric (likely) pathogenic variant carriers stratified by polygenic score (PRSHCM) below (dark orange) vs. above (dark red) the median. Numbers at risk in each group along the time scale shown at the bottom of the plot. Ticks along the survival curves represent subject censoring. Two-sided log-rank test P = 0.032 (Cox proportional hazard analysis P = 9 × 10-3; see Supplementary Table 21).